FDA Inspection 853505 — Novacyl Wuxi Pharmaceutical Co., Ltd.
The FDA completed an inspection of Novacyl Wuxi Pharmaceutical Co., Ltd. on October 18, 2013 in Wuxi. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- October 18, 2013
- Fiscal Year
- 2014
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuxi (China)